Ascendis Pharma, Inc.
500 Emerson Street
Palo Alto
CA
94301
United States
Tel: 650-352-8389
Fax: 650-618 -592
Website: http://www.ascendispharma.com/
Email: info@ascendispharma.com
143 articles with Ascendis Pharma, Inc.
-
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism
11/14/2022
Ascendis Pharma A/S announced it has submitted a Marketing Authorisation Application to the European Medicines Agency for TransCon PTH in adult patients with hypoparathyroidism.
-
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years
11/13/2022
Ascendis Pharma A/S announced positive topline results from the ACcomplisH Trial, its Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial evaluating the safety and efficacy of once-weekly TransCon CNP compared to placebo in children with achondroplasia aged 2 to 10 years old.
-
Frazier Life Sciences Adds Experienced Biopharmaceutical Executive to Team
10/4/2022
Frazier Life Sciences announced the addition of Jan Møller Mikkelsen as a Senior Advisor. He has over 30 years of experience as a biopharmaceutical executive.
-
At ENDO 2022, Ascendis will share Phase II and III data showing clinical efficacy for its investigational product candidate for hypoparathyroidism. For this and more, see inside.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update Conference Call on May 11
5/4/2022
Ascendis Pharma A/S announced that the company will hold a conference call and live webcast on Wednesday, May 11, 2022 at 4:30 p.m. Eastern Time to review its first quarter 2022 financial results and provide a business update.
-
Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May 2022
5/1/2022
Ascendis Pharma A/S announced that the company will present clinical and research outcomes and host informational booths and events at four medical meetings during May.
-
Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering
3/25/2022
Ascendis Pharma A/S announced the pricing of its offering of US$500,000,000 aggregate principal amount of 2.25% convertible senior notes due 2028 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Ascendis Pharma Announces Proposed Convertible Senior Notes Offering - Mar 23, 2022
3/23/2022
Ascendis Pharma A/S announced its intention to offer, subject to market and other conditions, US$500,000,000 aggregate principal amount of convertible senior notes due 2028 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
It was a busy week for clinical trial announcements. Here's a look.
-
This week is starting off strong with some positive clinical news from Ascendis Pharma, Can-Fite and BridgeBio.
-
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints
3/13/2022
Ascendis Pharma A/S announced that top-line data from the randomized, double-blind, placebo-controlled portion of its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant improvement with TransCon PTH compared to control on the primary composite endpoint and all key secondary endpoints.
-
Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update
3/2/2022
Ascendis Pharma A/S announced financial results for the full year ended December 31, 2021 and provided a business update.
-
FDA rejected OPKO's once-weekly human growth hormone, somatrogon, which it co-developed with Pfizer for the treatment of growth hormone deficiency (GHD) in pediatric patients.
-
Ascendis Pharma A/S - Share Repurchase Program Update
11/8/2021
Ascendis Pharma A/S provided an update on the Company’s previously announced $25 million American Depositary Shares Share Repurchase Program.
-
Ascendis Pharma A/S Announces Share Repurchase Program
9/29/2021
Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, announced that its Board of Directors has authorized the Company to repurchase up to $25 million of the Company’s American Depositary Shares, each of which represents one ordinary share of Ascendis Pharma A/S.
-
From time to time, the U.S. FDA requests additional data from companies who have submitted an application for a new drug or biologic. What’s a bit unusual is every single PDUFA date this week had that happen.
-
Ascendis Pharma A/S Announces Upcoming Investor Presentations - Sep 07, 2021
9/7/2021
Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, announced that the company will participate in two upcoming investor conferences.
-
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - Aug 31, 2021
8/31/2021
Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, announced that it has commenced an underwritten public offering of $400,000,000 of American Depositary Shares, each of which represents one ordinary share of Ascendis.